Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601167 | 0.86 | KDM4E (0.50) | KDM4EMAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL603951 | 0.83 | MAPT (0.58) | KDM4EMAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL603770 | 0.83 | KDM4E (0.51) | KDM4EMAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL603545 | 0.82 | CTSS (0.52) | KDM4EMAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL603342 | 0.82 | KDM4E (0.48) | KDM4EMAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL19862133 | 0.81 | GABRA1 (0.54) | KDM4EMAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL10039374 | 0.80 | KMT2A (0.60) | KDM4EMAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL19164377 | 0.79 | GABRA1 (0.56) | KDM4EMAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL17051424 | 0.79 | GABRA1 (0.56) | KDM4EMAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL27848601 | 0.79 | MAPT (0.45) | KDM4EMAPTGAASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102428082-A | Pyrimidine compounds and their use in pest control | SUMITOMO CHEMICAL CO | 2012-04-25 | — | — | CN | disclosed |
| EP-2432780-A1 | PYRIMIDINE COMPOUND AND ITS USE IN PEST CONTROL | Sumitomo Chemical Company, Limited (JP) | 2012-03-28 | — | — | EP | disclosed |
| US-20120041009-A1 | PYRIMIDINE COMPOUND AND ITS USE IN PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120041009-A1 | PYRIMIDINE COMPOUND AND ITS USE IN PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120041009-A1 | PYRIMIDINE COMPOUND AND ITS USE IN PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| WO-2010134478-A1 | PYRIMIDINE COMPOUND AND ITS USE IN PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041009-A1 | PYRIMIDINE COMPOUND AND ITS USE IN PEST CONTROL | TYMP, DPYD, TYMS | KDM4E 1030/4885MAPT 3666/4885GAA 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.